Fatty liver is usually silent and cannot be felt. Risk is driven by obesity, type 2 diabetes or prediabetes, high triglycerides, low HDL and hypertension. Normal liver enzymes do not rule it out. The pathway runs from risk factors to a FIB-4 score, then to imaging or elastography where indicated. What follows builds a risk picture rather than a diagnosis.
Fat in the liver is common. The feature that predicts outcomes is fibrosis (scarring), so the question driving assessment is not whether fat is present but whether scarring is likely. → What Is MASLD?
From risk to a reasonable next step
Step 1 · Risk factors — who gets MASLD
MASLD (metabolic dysfunction-associated steatotic liver disease) travels with metabolic risk, and each additional factor raises the pre-test probability:
- Obesity, especially central adiposity.
- Type 2 diabetes or prediabetes — a majority of people with type 2 diabetes have MASLD, and diabetes drives progression. → MASLD & Diabetes
- High triglycerides, low HDL, hypertension — the metabolic-syndrome cluster.
- Family history of cirrhosis or liver disease, and certain ethnic-genetic risk.
- Alcohol, which changes the classification: significant alcohol intake alongside metabolic risk is MetALD rather than pure MASLD. → What Is MASLD?
Step 2 · Symptoms
Most fatty liver disease is silent. There is usually no pain and no obvious symptom until the disease is advanced, so the absence of symptoms carries almost no information about whether MASLD or fibrosis is present. Assessment therefore rests on risk factors and scores rather than on how a person feels, and feeling well does not lower risk when the risk factors are there.
Step 3 · What liver enzymes do and do not show
Normal liver tests are frequently taken to mean a healthy liver, and the two are not equivalent.
- ALT and AST measure liver-cell injury, not liver fat and not scarring.
- MASLD, and even significant fibrosis, can occur with completely normal enzymes. Enzyme values can fall as disease advances.
- Normal enzymes are therefore mildly reassuring at most and do not rule out at-risk liver disease. (Grade A 🟢)
A normal liver panel does not close the question in the presence of metabolic risk. → My Liver Tests Are Normal…
Step 4 · Ultrasound — good at fat, not at scarring
Where imaging, often an abdominal ultrasound performed for another reason, reports a fatty liver, it confirms steatosis — fat. Ultrasound detects fat reasonably well but does not measure fibrosis, the outcome-relevant feature. A reported fatty liver is therefore a prompt to assess fibrosis risk, and confirmed fat with unknown fibrosis risk is the usual starting position. (Grade A 🟢) → Diagnostic Approach
Step 5 · FIB-4 — the fibrosis-risk filter
FIB-4 is the recommended first step for estimating advanced-fibrosis risk. It uses four routine values — age, AST, ALT and platelet count — so it often requires no new test, and because it weights age and platelets it catches risk that normal enzymes miss.
| FIB-4 | Meaning | Reasonable next step |
|---|---|---|
| < 1.3 | Low risk — strong rule-out for advanced fibrosis | Reassurance; manage metabolic risk; recheck periodically |
| 1.3 – 2.67 | Indeterminate | Elastography (ultrasound shear-wave elastography) to clarify |
| > 2.67 | High risk | Elastography and/or hepatology referral |
- Age ≥ 65: the lower cutoff is raised to about 2.0 to reduce false positives.
- A low FIB-4 is genuinely reassuring; a high FIB-4 is a flag, not a diagnosis. (Grade A 🟢) → FIB-4 Explained
The FIB-4 band determines whether the next step is monitoring or further testing.
Step 6 · When elastography is appropriate
Elastography — ultrasound shear-wave elastography, or MRE — physically measures liver stiffness (kPa) as a fibrosis surrogate, and the same ultrasound examination reports UDFF (ultrasound-derived fat fraction) for fat. It is the appropriate next step when FIB-4 is indeterminate or high, or when risk is high, as in diabetes, and better fibrosis assessment is warranted.
Elastography is more accurate for fibrosis than blood scores or ultrasound, is non-invasive, and spares many people a biopsy. Biopsy remains the reference standard for selected uncertain cases only. It is a test for people whose FIB-4 or risk profile indicates a closer look, not a first test for everyone. (Grade A 🟢) → Elastography & Liver Fat · Liver Biopsy
Step 7 · When evaluation is warranted
Fibrosis-risk assessment is worth raising with a clinician in the presence of:
- Type 2 diabetes or prediabetes, obesity or central adiposity, or the metabolic-syndrome cluster.
- An incidentally discovered fatty liver on any scan.
- An elevated ALT or AST, a low platelet count, or an already-high FIB-4.
- Significant alcohol use alongside metabolic risk.
Metabolic risk alone is sufficient reason to assess, even with normal enzymes. → Who Should Be Evaluated?
What this pathway produces
The output of the sequence is a risk picture and a next step, not a stage. A typical result reads: obesity and prediabetes with an incidental fatty liver on ultrasound, where normal enzymes do not rule out fibrosis, so the reasonable next step is a FIB-4, followed by elastography if that score is indeterminate or high. Staging liver disease — distinguishing MASH or cirrhosis — requires a clinician and the appropriate tests. → Request an appointment
What the evidence says: assessing fatty-liver risk
- What we know: MASLD is common and usually silent; it tracks with metabolic risk; normal enzymes do not exclude it or fibrosis; FIB-4 is a validated first-line filter and elastography a strong second step.
- What we think: risk-based assessment — risk factors, then FIB-4, then elastography where needed — identifies the people with fibrosis risk while sparing the low-risk majority unnecessary testing.
- What we don't know: the single best population-screening strategy, and the ideal enzyme thresholds.
- In our practice: risk is judged on risk factors and FIB-4 rather than on symptoms or a single liver panel, and an at-risk result leads to a clinical evaluation. → Request an appointment
Questions patients ask
What are the symptoms of fatty liver?
Usually none — it is typically silent until advanced. Feeling well does not lower risk, which is why assessment is based on risk factors and scores rather than symptoms. Grade A 🟢
Liver enzymes are normal — does that settle it?
Not necessarily. ALT and AST measure liver-cell injury, not fat or scarring, and fatty liver, including significant fibrosis, can occur with normal enzymes. Where metabolic risk is present, a FIB-4 is still worthwhile. Grade A 🟢 → Normal enzymes
What is a FIB-4 and where does it come from?
It is a fibrosis-risk score calculated from age, AST, ALT and platelet count, values often already present on routine bloodwork. Under 1.3 is low risk; higher bands prompt elastography. A clinician calculates and interprets it. Grade A 🟢 → FIB-4 Explained
Is liver elastography always needed?
No. Liver elastography is the next step mainly when FIB-4 is indeterminate or high, or when risk such as diabetes warrants a closer look, rather than as a first test in low-risk people. Grade A 🟢 → Elastography & Liver Fat
Is fatty liver reversible?
The fat often improves substantially with weight loss and metabolic management — roughly ≥5% loss reduces steatosis, ≥7–10% improves MASH. Reversing fibrosis requires larger, sustained change, and maintenance counts. Grade A 🟢 → Fatty Liver & Weight Loss
Is there a treatment once it is confirmed?
Yes. Weight loss and metabolic management are foundational, and for confirmed noncirrhotic MASH with F2–F3 fibrosis there are now FDA-approved drugs (resmetirom; semaglutide 2.4 mg). Confirming the stage is what determines eligibility. Grade A 🟢 → MASH Medications
Where a particular risk picture sits, and which test follows from it, is assessed individually at the practice.
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: Oct 2026 · References: AASLD Practice Guidance on MASLD (2023); EASL–EASD–EASO guidance; guideline-based FIB-4 cutoffs (<1.3 / >2.67; age-adjusted ~2.0 at ≥65); 2023 MASLD/MetALD nomenclature. Educational only; not a diagnosis and not individualized medical advice.
